Indacaterol
This ultra-long-acting beta-2 agonist (LABA) bronchodilator is inhaled once daily for the maintenance treatment of COPD and asthma. It relaxes the smooth muscle surrounding the airways, improving airflow and reducing breathlessness throughout the day. It is used as a maintenance medication and does not provide rapid relief during an acute attack.
分子量
392.5000 g/mol
LogP
3.30
TPSA
81.60 Ų
Lipinski 五规则
符合
治疗领域
作用机制
Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.
二维结构
Cite this structure
Embed this structure
SMILES
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2
InChI
InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
Molecular Formula
C24H28N2O3
HBD / HBA
4 / 4
可旋转键数
6
重原子数
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
This ultra-long-acting beta-2 agonist (LABA) bronchodilator is inhaled once daily for the maintenance treatment of COPD and asthma. It relaxes the smooth muscle surrounding the airways, improving airflow and reducing breathlessness throughout the day. It is used as a maintenance medication and does not provide rapid relief during an acute attack.
Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.
Yes, Indacaterol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1095777. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6918554. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="indacaterol"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/indacaterol/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/indacaterol/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/indacaterol/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="indacaterol"></drugfyi-drug>